CN104367578A - Dissolving method for cefoperazone sodium-tazobactam sodium for injection - Google Patents
Dissolving method for cefoperazone sodium-tazobactam sodium for injection Download PDFInfo
- Publication number
- CN104367578A CN104367578A CN201410481481.2A CN201410481481A CN104367578A CN 104367578 A CN104367578 A CN 104367578A CN 201410481481 A CN201410481481 A CN 201410481481A CN 104367578 A CN104367578 A CN 104367578A
- Authority
- CN
- China
- Prior art keywords
- injection
- sodium
- solvent
- drug
- dissolving method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a dissolving method for cefoperazone sodium-tazobactam sodium for injection. According to the dissolving method, a solvent is slowly added to a drug container during injecting, the needle does not contact the drug, and the drug container is uniformly shaken until all the solvent enters the drug container so as to obtain the completely-dissolved, clear and transparent drug agent, wherein the solvent selects sterile water for injection, a xylitol injection or a 0.9% sodium chloride injection to dissolve. With the dissolving of the invention, the drug can be effectively dissolved so as to make the solution present the clear and transparent state and easily achieve the control of the drug quality stability.
Description
Technical field
The present invention relates to field of pharmaceutical biology, particularly, relate to the dissolving method of Cefoperazone Sodium and Tazobactam.
Background technology
Chinese another name 7-(((the 4-ethyl-2 of cefoperazone sodium, 3-dioxo-1-piperazinyl) formamido group) (4-hydroxy phenyl) acetylamino)-3-((1-methyl isophthalic acid H-tetrazolium-5-base) sulfidomethyl)-8-oxo-5-sulfur-1-azabicyclo (4.2.0) oct-2-ene-2-formic acid sodium salt, certain stability is had to the wide spectrum beta-lactamase that negative bacillus produces, but comparatively some third generation cephalosporin is poor, the effect of anti-negative bacillus is better than first and second cephalosporin in generation, but has good antibacterial activity to bacillus pyocyaneus.The effect of anti-positive bacterium not as first and second cephalosporin, but all has good effect to streptococcus pneumoniae, micrococcus scarlatinae in generation.More weak to the antibacterial action of anaerobe.The enterobacteriaceae pathogenic bacterium of enterococcus and significant proportion are to this product drug resistance, and mycoplasma, chlamydia, legionella are to the equal drug resistance of cefoperazone.Anti-microbial property is similar to cefotaxime.More weak to the effect of gram positive bacteria, only Hemolytic streptococcus and streptococcus pneumoniae are comparatively responsive.The gram-negative bacteria of logarithm, the effect of these product is slightly inferior to cefotaxime, stronger to the effect of bacillus pyocyaneus.For the treatment of the various infection that responsive zymogenic bacteria causes, as the treatment of respiratory system, urogenital system, biliary tract, gastrointestinal tract, splanchnocoel, skin soft-tissue infection, and also there is good curative effect to the brain inner infection that hemophilus influenza, meningococcus cause.The infection that treatment bacillus pyocyaneus causes, cefoperazone is a good third generation cephalosporin.
Sodium-tazobactam and penicillins and cephalosporins have obvious synergism, therefore clinically usually by sodium-tazobactam and penicillins, cephalosporins combination formulations to strengthen the drug effect of single medicament.But clinical staff finds to be suspended with a little white, needle-shaped crystals body in preparation transfusion often, and jolting does not disappear, and the direct injection that such suspension obviously cannot be relieved is to patient.
Summary of the invention
Technical problem to be solved by this invention is to provide the dissolving method of Cefoperazone Sodium and Tazobactam, and this dissolving method effectively can dissolve medicine, and makes solution present the state of clear, is conducive to the control of drug quality stability.
The present invention's adopted technical scheme that solves the problem is:
The dissolving method of Cefoperazone Sodium and Tazobactam, during injection, solvent is slowly added in medicament reservoir, syringe needle does not contact medicine, all enter after medicament reservoir until solvent and medicament reservoir is shaken up, the medicament dissolving complete clear can be obtained, described solvent select sterilized water for injection, Xylitol injection or 0.9% sodium chloride injection dissolve.
Further, described solvent is sterilized water for injection.The dissolution time that the sodium chloride injection of 0.9% and xylitol solution need when dissolving cefoperazone sodium and tazobactam sodium is longer, therefore the first-selected sterilized water for injection of solvent.
Further, the acid-base value deflection alkalescence of described water for injection.Under certain cefoperazone concentration, medicinal liquid becomes muddy degree and reduces along with pH value and strengthen, and therefore dissolves with the solvent that pH value is higher as far as possible.
Further, avoid when shaking up described in firmly rocking output foam.
To sum up, the invention has the beneficial effects as follows:
The present invention effectively can be dissolved medicine, and makes solution present the state of clear, is conducive to the control of drug quality stability.
Detailed description of the invention
Below in conjunction with embodiment, to the detailed description further of the present invention's do, but embodiments of the present invention are not limited thereto.
Embodiment 1:
The dissolving method of Cefoperazone Sodium and Tazobactam, during injection, solvent is slowly added in medicament reservoir, syringe needle does not contact medicine, all enter after medicament reservoir until solvent and medicament reservoir is shaken up, the medicament dissolving complete clear can be obtained, described solvent select sterilized water for injection, Xylitol injection or 0.9% sodium chloride injection dissolve.
Further, described solvent is sterilized water for injection.The dissolution time that the sodium chloride injection of 0.9% and xylitol solution need when dissolving cefoperazone sodium and tazobactam sodium is longer, therefore the first-selected sterilized water for injection of solvent.
Further, the acid-base value deflection alkalescence of described water for injection.Under certain cefoperazone concentration, medicinal liquid becomes muddy degree and reduces along with pH value and strengthen, and therefore dissolves with the solvent that pH value is higher as far as possible.
Further, avoid when shaking up described in firmly rocking output foam.Different pharmaceutical has different chemical constitutions and physicochemical property in addition, therefore, when preparing transfusion, preferably selecting single solvent to carry out medicine dissolution, and then the interaction between ingredient can be reduced, avoid the unstability of effective ingredient, ensure that the drug effect of medicine is given full play to.
Claims (4)
1. the dissolving method of Cefoperazone Sodium and Tazobactam, it is characterized in that, during injection, solvent is slowly added in medicament reservoir, syringe needle does not contact medicine, all enter after medicament reservoir until solvent and medicament reservoir is shaken up, the medicament dissolving complete clear can be obtained, described solvent select sterilized water for injection, Xylitol injection or 0.9% sodium chloride injection dissolve.
2. dissolving method according to claim 1, is characterized in that, described solvent is sterilized water for injection.
3. dissolving method according to claim 2, is characterized in that, the acid-base value deflection alkalescence of described water for injection.
4. the dissolving method according to any one of claim 1-3, is characterized in that, described in avoid firmly rocking output foam when shaking up.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410481481.2A CN104367578A (en) | 2014-09-21 | 2014-09-21 | Dissolving method for cefoperazone sodium-tazobactam sodium for injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410481481.2A CN104367578A (en) | 2014-09-21 | 2014-09-21 | Dissolving method for cefoperazone sodium-tazobactam sodium for injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104367578A true CN104367578A (en) | 2015-02-25 |
Family
ID=52546942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410481481.2A Pending CN104367578A (en) | 2014-09-21 | 2014-09-21 | Dissolving method for cefoperazone sodium-tazobactam sodium for injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104367578A (en) |
-
2014
- 2014-09-21 CN CN201410481481.2A patent/CN104367578A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 刘兵等: "注射用头孢哌酮钠他唑巴坦钠的溶解方法及注意事项, 刘兵等，《中国药房》， 2007 年第18 卷第22 期，第1726页", 《中国药房》 * |
| 吴敏: "注射用头孢哌酮钠与5 种常用输液的配伍稳定性分析, 吴敏, 《海峡药学》 2010年第22卷第3期，第14-16页", 《海峡药学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103732232B (en) | Comprise the compositions of antibiotic and dispersant or caking inhibiter | |
| CN102670497A (en) | Stable S-oxiracetam preparation for injection and preparation method of same | |
| US20170281824A1 (en) | Anti-Microbial Medical Materials and Devices | |
| RU2010114023A (en) | APPLICATION OF THE PEPTIDE Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu-OH AS A THERAPEUTIC | |
| CN101632671A (en) | Suspensoid powder injection of piperacillin sodium sulbactam sodium medicine composition and novel application thereof | |
| CN102405935B (en) | Protamine compounded preparation, preparation method and application thereof | |
| CN107921102B (en) | Combination therapy | |
| CN101773478B (en) | Pulmonary targeting microsphere of veterinary ceftiofur hydrochloride and preparation method thereof | |
| CN104367578A (en) | Dissolving method for cefoperazone sodium-tazobactam sodium for injection | |
| CN103951679B (en) | A kind of cefoperazone sodium compound and pharmaceutical composition thereof | |
| CN104095847A (en) | Pharmaceutical composition containing imipenem cilastatin sodium and preparation thereof | |
| CN102626381A (en) | Vesicular phospholipid gel injection of latamoxef sodium | |
| CN103919779B (en) | A kind of pharmaceutical composition containing Moxifloxacin | |
| CN104367579A (en) | Preparation method for cefoperazone sodium-tazobactam sodium for injection | |
| CN104382908A (en) | Cefoperazone sodium tazobactam sodium composition for injection | |
| CN102125562A (en) | Medicinal composition for injection for treating superbug | |
| CN103110641A (en) | Pharmaceutical composition of injection cefodizime sodium and lidocaine hydrochloride injection | |
| CN107801732A (en) | Gas humidification liquid and preparation method thereof | |
| CN101579307A (en) | Application of hypertonic injection to preparation of medicament accelerating wound healing | |
| CN104546742A (en) | Pantoprazole sodium drug for injection and preparation method thereof | |
| CN102240266A (en) | Preparation method of aseptic powder containing loniefloxacin aspertate for injection | |
| CN102824310A (en) | Cefotiam-hydrochloride-containing medicine preparation and preparation method thereof | |
| CN104436176A (en) | Novel biological antibacterial spray for upper respiratory infection and pneumonia | |
| JP2008100926A (en) | Catheter-locking solution | |
| CN103585171A (en) | Aztreonam composition freeze-dried powder for injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150225 |